fashion -WSS

fashion

author：focus 2025-10-01 15:30:13 - browse：788

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Novo acquires Inversago for up to $1 billion

hotspot

WSS

Judge orders hearing on Trump's motion to disqualify Fulton County DA

After John Oliver segment, STAT readers share their opioid

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

The perfect storm of weather conditions that led to the devastating wildfires in Maui

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

focus

fashion

knowledge

23andMe had bad news about my health. I wish a person had delivered it

Campaign finance charge dropped from case against Sam Bankman

How to save PrEP access — and even expand it

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Psychedelics group wrestles with new pharma identity

Teacher posts viral 'school supply rant' with advice for parents

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

ChatGPT in medicine: STAT answers readers' burning questions

Target recalls 2.2 million additional candles due to laceration, burn hazards

focus

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

Typhoon Doksuri makes landfall in China after bringing deadly landslides to Philippines

Pharma budget tightening trickles down to Doximity

Typhoon Doksuri makes landfall in China after bringing deadly landslides to Philippines

Newly revealed memo details efforts to keep Trump in power following election loss

Faced with fears of OxyContin misuse, sales reps touted its safety

hotspot

explore

leisure time

hotspot